MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on June 17, 2008; DOI: 10.1124/mol.108.046417


0026-895X/08/7403-641-653$20.00
Mol Pharmacol 74:641-653, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
mol.108.046417v1
mol.108.046417v2
74/3/641    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Mathiasen, L.
Right arrow Articles by Andreasen, P. A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mathiasen, L.
Right arrow Articles by Andreasen, P. A.

A Peptide Accelerating the Conversion of Plasminogen Activator Inhibitor-1 to an Inactive Latent State

Lisa Mathiasen, Daniel M. Dupont, Anni Christensen, Grant E. Blouse, Jan K. Jensen, Ann Gils, Paul J. Declerck, Troels Wind, and Peter A. Andreasen

Department of Molecular Biology, Aarhus University, Denmark (L.M., D.M.D., A.C., G.E.B., J.K.J., T.W., P.A.A.); and Laboratory for Pharmaceutical Biology, Faculty of Pharmaceutical Sciences, Katholieke Universiteit, Leuven, Belgium (A.G., P.J.D.)

The serpin plasminogen activator inhibitor-1 (PAI-1) is a specific inhibitor of plasminogen activators and a potential therapeutic target in cancer and cardiovascular diseases. Accordingly, formation of a basis for development of specific PAI-1-inactivating agents is of great interest. One possible inactivation mode for PAI-1 is conversion to the inactive, so-called latent state. We have now screened a phage-displayed peptide library with PAI-1 as bait and isolated a 31-residue cysteine-rich peptide that will be referred to as paionin-4. A recombinant protein consisting of paionin-4 fused to domains 1 and 2 of the phage coat protein g3p caused a 2- to 3-fold increase in the rate of spontaneous inactivation of PAI-1. Paionin-4-D1D2 bound PAI-1 with a KD in the high nanomolar range. Using several biochemical and biophysical methods, we demonstrate that paionin-4-D1D2-stimulated inactivation consists of an acceleration of conversion to the latent state. As demonstrated by site-directed mutagenesis and competition with other PAI-1 ligands, the binding site for paionin-4 was localized in the loop between {alpha}-helix D and β-strand 2A. We also demonstrate that a latency-inducing monoclonal antibody has an overlapping, but not identical binding site, and accelerates latency transition by another mechanism. Our results show that paionin-4 inactivates PAI-1 by a mechanism clearly different from other peptides, small organochemical compounds, or antibodies, whether they cause inactivation by stimulating latency transition or by other mechanisms, and that the loop between {alpha}-helix D and β-strand 2A can be a target for PAI-1 inactivation by different types of compounds.


Received February 17, 2008; accepted June 17, 2008

Address correspondence to: Peter A. Andreasen, Laboratory of Cellular Protein Science, Department of Molecular Biology, Aarhus University, 10C Gustav Wied's Vej, 8000 Aarhus C, Denmark. E-mail: pa{at}mb.au.dk




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
C. R. Schar, J. K. Jensen, A. Christensen, G. E. Blouse, P. A. Andreasen, and C. B. Peterson
Characterization of a Site on PAI-1 That Binds to Vitronectin Outside of the Somatomedin B Domain
J. Biol. Chem., October 17, 2008; 283(42): 28487 - 28496.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics